Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01962467

A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine

Rhinitis, Allergic, Perennial and Seasonal Clinical Trial

Official title:
A Relative Bioavailability Study to Compare the Pharmacokinetics of a Fixed Dose Combination of Fluticasone Furoate and Levocabastine With Levocabastine and Fluticasone Furoate Alone

Clinical Trial Summary

This is an open label, randomized, 3-way cross-over, and repeat administration study in healthy male and female subjects. The purpose of the study is to determine the relative bioavailability of Fluticasone Furoate (FF) and Levocabastine (LEV), when each is administered alone and as FF/LEV Fixed Dose Combination (FDC).This study consists of Part A (in which 30 subjects including 12 Korean subjects will be enrolled) and Part B (in which 18 subjects will be enrolled). Each part will consist of three treatment periods separated by a minimum washout period of 14 days. In each treatment period, subjects will receive seven daily doses of one of the 3 treatments: FF, LEV or FF/LEV FDC, via an intranasal spray according to one of the 6 possible randomization sequences. The study will use an adaptive design with an interim review following Part A to confirm whether Part B is required.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01962467
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date October 11, 2013
Completion date February 27, 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT02424539 - A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR) Phase 4
Completed NCT01949051 - A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis Phase 2
Completed NCT01957202 - A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR) Phase 2
Completed NCT01001130 - Regulatory AVAMYS Nasal Spray PMS N/A
Completed NCT01622283 - Pharmacokinetic Study of Levocetirizine Oral Solution Phase 1
Completed NCT02397915 - Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays Phase 4
Completed NCT01445262 - Drug Use Investigation for XYZAL® N/A
Completed NCT01916226 - A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis Phase 4
Completed NCT00109486 - Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal Spray Phase 3